| Literature DB >> 28183232 |
Hui-Fang Chiu1, Hui-Yu Fu2, Yan-Ying Lu3, Yi-Chun Han2, You-Cheng Shen4, Kamesh Venkatakrishnan2, Oksana Golovinskaia5, Chin-Kun Wang2.
Abstract
CONTEXT: Ganoderma lucidum (Leyss: Fr) Karst. (Polyporaceae) is an oriental medicinal fungus, commonly used in traditional Chinese medicine (TCM) for treating various condition or diseases such as hypertension, hyperglycaemia, hepatitis and cancer.Entities:
Keywords: Oxidative stress; fatty liver; hepatic markers; ultrasonic examination
Mesh:
Substances:
Year: 2017 PMID: 28183232 PMCID: PMC6130508 DOI: 10.1080/13880209.2017.1288750
Source DB: PubMed Journal: Pharm Biol ISSN: 1388-0209 Impact factor: 3.503
Figure 1.Flow chart of present study.
The anthropometric parameters in GL and placebo-treated healthy subjects.
| Group | Height (cm) | Weight (Kg) | Body fat (%) | BMI (kg/m2) | |
|---|---|---|---|---|---|
| Baseline | GL | 165.24 ± 8.55a | 63.63 ± 10.75a | 26.06 ± 4.68a | 23.22 ± 2.93a |
| Placebo | 164.78 ± 10.11a | 63.75 ± 10.89a | 25.37 ± 4.28a | 23.26 ± 2.97a | |
| Third month | GL | 165.24 ± 8.55a | 62.98 ± 10.98a | 25.79 ± 4.20a | 22.95 ± 3.02a |
| Placebo | 164.78 ± 10.11a | 63.55 ± 11.45a | 26.23 ± 4.00a | 23.19 ± 3.18a | |
| Sixth month | GL | 165.24 ± 8.55a | 63.36 ± 11.01a | 25.91 ± 4.54a | 22.97 ± 3.31a |
| Placebo | 164.78 ± 10.11a | 63.18 ± 11.09a | 26.43 ± 4.47a | 23.05 ± 3.06a |
Values were expressed as means ± SD (n = 39). Data within the same column of each group sharing different superscript letters were significantly different (p < 0.05).
BMI: body mass index; GL: Ganoderma lucidum.
Various plasma oxidative indexes in GL and placebo-treated healthy subjects.
| Group | TEAC (%) | TBARS (μM/L) | 8-OH-dG (pg/mL) | Thiols (mM/mL) | GSH (μM/L) | |
|---|---|---|---|---|---|---|
| Baseline | GL | 79.33 ± 4.95a | 3.37 ± 0.47a | 15.99 ± 2.39a | 0.19 ± 0.04b | 6.00 ± 1.07b |
| Placebo | 80.70 ± 5.04a | 3.26 ± 0.44a | 14.70 ± 3.00a | 0.21 ± 0.06a | 6.90 ± 1.48a | |
| Third month | GL | 82.93 ± 3.087a | 3.28 ± 0.81a | 14.49 ± 2.72a | 0.20 ± 0.05b | 7.30 ± 1.66a |
| Placebo | 80.97 ± 3.98a | 3.32 ± 0.73a | 15.19 ± 2.99a | 0.20 ± 0.07a | 6.66 ± 1.63a | |
| Sixth month | GL | 84.04 ± 3.74b | 2.47 ± 0.68b | 11.98 ± 1.79b | 0.28 ± 0.05a | 8.05 ± 1.42a |
| Placebo | 80.24 ± 3.79a | 3.30 ± 0.88a | 15.35 ± 3.07a | 0.19 ± 0.06a | 6.63 ± 1.39a |
Values were expressed as means ± SD (n = 39). Data within the same column of each group bearing different superscript letters were significantly different (p < 0.05).
Erythrocyte antioxidative enzymes in GL and placebo-treated healthy subjects.
| Group | SOD (IU/g Hb) | CAT (IU/g Hb) | G-6-PDH (IU/g Hb) | GPx (IU/g Hb) | GR (IU/g Hb) | |
|---|---|---|---|---|---|---|
| Baseline | GL | 1155.98 ± 150.11c | 246.26 ± 28.08b | 11.99 ± 1.99b | 13.16 ± 1.71b | 4.00 ± 0.61a |
| Placebo | 1143.95 ± 170.14a | 245.83 ± 32.43a | 11.83 ± 2.11b | 12.64 ± 1.43a | 3.95 ± 0.64a | |
| Third month | GL | 1244.73 ± 149.46b | 268.87 ± 28.22ab | 12.40 ± 2.26b | 14.39 ± 1.20b | 4.29 ± 0.66a |
| Placebo | 1141.25 ± 155.46a | 244.86 ± 31.80a | 11.93 ± 2.19a | 13.07 ± 1.53a | 3.99 ± 0.63a | |
| Sixth month | GL | 1385.63 ± 139.01a | 279.21 ± 26.18a | 13.56 ± 2.11a | 15.44 ± 1.17a | 4.53 ± 0.68a |
| Placebo | 1144.60 ± 150.73a | 242.97 ± 28.32a | 11.94 ± 2.03a | 12.63 ± 1.78a | 3.99 ± 0.63a |
Values were expressed as means ± SD (n = 39). Data within the same column of each group bearing different superscript letters were significantly different (p < 0.05).
The hepatic marker enzymes in plasma of GL and placebo-treated healthy subjects.
| Group | GPT (U/L) | GOT (U/L) | |
|---|---|---|---|
| Baseline | GL | 22.58 ± 5.13a | 20.65 ± 4.37a |
| Placebo | 20.05 ± 4.93a | 19.65 ± 5.46a | |
| Third month | GL | 16.85 ± 3.46 b | 19.85 ± 4.63a |
| Placebo | 20.25 ± 3.94a | 20.45 ± 4.74a | |
| Sixth month | GL | 13.08 ± 2.79c | 15.50 ± 3.17b |
| Placebo | 21.33 ± 5.11a | 19.90 ± 4.83a |
Values were expressed as means ± SD (n = 39). Data within the same column of each group bearing different superscript letters were significantly different (p < 0.05).
Figure 2.The abdominal ultrasonic image of GL-treated healthy subjects. Image A, B and C represents subject no. 10, 19 at baseline with mild fatty liver and subject no. 36 at baseline with gall bladder polyp (indicated with a circle). Image D, E and F represents subject no. 10, 19 and 36 after 6 months of GL treatment display normal hepatic structure without any signs of fatty liver or gallbladder polyp.